Related Experiment Video
Updated: Aug 11, 2026
06:21
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
CA 19-9 in pancreatic cancer
Surgical Oncology Clinics of North America
|March 7, 1998
Summary
Cancer antigen 19-9 (CA 19-9) is vital for diagnosing, predicting, and monitoring pancreatic cancer. Elevated CA 19-9 levels aid in diagnosis and prognosis, while changes reflect treatment response.
Area of Science:
- Oncology
- Biomarker Research
- Gastroenterology
Background:
- Pancreatic cancer diagnosis and management remain challenging.
- CA 19-9 is a widely used tumor marker in this context.
Purpose of the Study:
- To elucidate the defined role of CA 19-9 in pancreatic cancer.
- To highlight its utility in diagnosis, prognosis, and therapy monitoring.
Main Methods:
- Review of clinical data and diagnostic criteria for CA 19-9 in pancreatic cancer.
- Analysis of CA 19-9 levels in relation to diagnostic confirmation (e.g., CT scan).
- Correlation of preoperative and postoperative CA 19-9 levels with patient outcomes and treatment response.
Main Results:
- A CA 19-9 reference value >200 u/mL in nonjaundiced patients with CT confirmation shows high diagnostic predictive value.
- Low preoperative CA 19-9 and normalization post-resection predict favorable prognosis.
- CA 19-9 levels effectively monitor response to neoadjuvant therapy.
Conclusions:
- CA 19-9 is an established biomarker for pancreatic cancer diagnosis.
- Its levels provide critical prognostic information and are valuable for monitoring therapeutic efficacy.
- Integration of CA 19-9 with imaging and clinical status optimizes patient management.
